About VION Biosciences

Advancing Life Sciences with Innovation and Impact.

V (1)

Empowering
a World
of Discovery

V

Potential

Unlocking the Potential of Science

Scientific innovation drives progress. VION Biosciences empowers researchers and businesses with high-quality reagents, custom formulations, and biopharmaceutical solutions to advance healthcare, life sciences, and beyond.

about-image
V (2)

Pioneer

VION’s End-to-End Solutions in Life Sciences

VION Biosciences is driving progress in life sciences by scaling the VION Innovated Brand Portfolio, fostering collaboration, and expanding global reach.

001

VION Innovated Brand Portfolio

Bringing together industry leaders to accelerate scientific breakthroughs.

002

Synergy & Growth

Fostering collaboration and scalable solutions for lasting impact.

003

Global Impact

Delivering high-quality products and services to innovators worldwide.

V (1)

VION proudly supports a group of pioneering companies that are advancing science, healthcare, and technology.

VION’s portfolio offers integrated capabilities throughout the entire drug and diagnostic lifecycle, from discovery to commercialization and delivery.

V (2)

Scientific research is a catalyst for transformation. At VION, we provide the tools and expertise to fuel breakthrough discoveries.

Empowering
a World
of Discovery

success-image

VION Biosciences is driving breakthroughs across drug development, diagnostics, and therapeutic solutions.

Success

VION’s Diverse Portfolio of Innovators

From breakthrough biopharmaceuticals to precision diagnostics, our impact extends across industries. We empower innovation that drives scientific success with over 10,000 chemical compounds, a global distribution network, and custom solutions tailored to biopharma, diagnostics, and academia.

Pioneering Innovation

001

VION Innovated Brand Portfolio

img-5

002

Growth & Synergy

img-1

003

Global Impact

Vion Team

Meet the Vion Team

Mark Thornton

Mark Thornton

Chief Executive Officer

Mr. Thornton is a tenured life science industry executive with over 25 years of leadership experience in the biotechnology, clinical research, biochemical, and research sectors.

Vince Stoyanov

Vince Stoyanov

Chief Strategy and Development Officer

Vince Stoyanov is a senior executive with over 20 years of experience in the life sciences technology industry. He has proven expertise in enterprise-level strategy development, M&A;, and corporate business development across biotechnology, biomanufacturing, diagnostics, and advanced materials.

John Voycik

Vice President / Corporate and Business Development

Mr. Voycik has a combined 23 years in the life science and biotech space having served in a variety of roles from sales, marketing and business development.

Brian Korec

Vice President / Operations and Supply Chain

Mr. Korec is a highly diversified leader with 20 years of supply chain experience in the life science, biotechnology, and consumer product goods industries.

Heath Bowers, Phd

Vice President of Biopharma Market Solutions

Dr. Heath Bowers is a dynamic leader with over 15 years of experience at the intersection of science, strategy, and business development. His career is marked by transformative achievements that have propelled innovation and growth in the pharmaceutical and biopharma industries.

News

VION’s latest announcements, product launches, and milestones.

NASHVILLE, Tenn.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, announced its January 2025 acquisition of San Francisco area-based BioAssay Systems, a biotech company that develops and offers innovative high-throughput assay solutions for life sciences and drug discovery. This acquisition serves as the fourth investment under the VION platform, continuing its growth in developing proprietary products for life science research.
CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eufugiat nulla pariatur. Excepteur sint occaecat cupidatat non proidentsunt.
CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty reagents in the life science research, diagnostic, and drug discovery space, announced the recent acquisition of Salt Lake City-based Echelon Biosciences, a trusted supplier of critical materials, notably lipid-based excipients, to its growing portfolio. This acquisition serves as the second investment under VION Biosciences LLC (“VION Biosciences”), Iron Path Capital’s roll-up platform in the life science sector led by life science industry veteran, Mark Thornton.
V

Empowering
a World
of Discovery

Join us in advancing life sciences and creating transformative solutions.

Mark Thornton

Chief Executive Officer

Mr. Thornton is a tenured life science industry executive with over 25 years of leadership experience in the biotechnology, clinical research, biochemical, and research sectors.

Prior to establishing VION Biosciences in collaboration with Iron Path Capital, Mr. Thornton served as Vice President of the Sales Application group for Avantor, a Fortune 500 company. Ahead of its acquisition by Avantor in 2017, Mr. Thornton also held various leadership roles with VWR International, including serving as Vice President, Portfolio Management as well as Director, Custom Manufacturing Services. In these roles, Mr. Thornton led the commercial integration of several chemical manufacturing businesses across both North America and Europe which were acquired between 2011 and 2016 and were eventually combined to form VWR Chemicals, LLC. This included the acquisition of AMRESCO by VWR in 2011 where Mr. Thornton held various leadership roles from 2004 – 2011 that spanned various functions including Research & Development, Product Design & Engineering, and various Commercial functions including both Sales and Marketing. During this time, Mr. Thornton also gained significant international experience across Europe, Asia, and South America where he helped to grow and expand AMRESCO’s global footprint through a wide network of distributors across 72 countries in total.

Early on in Mr. Thornton’s career, he was trained in molecular biology and held various research roles in both the biotechnology and clinical research fields for both Athersys, Inc. and the Cleveland Clinic Foundation respectively.

Mr. Thornton currently serves on the Board of Directors for Nova Molecular Technologies as well as holds a B.S. degree in Molecular Biology and an M.B.A from Cleveland State University.

Vince Stoyanov

Chief Strategy and Development Officer

Vince Stoyanov is a senior executive with over 20 years of experience in the life sciences technology industry. He has proven expertise in enterprise-level strategy development, M&A;, and corporate business development across biotechnology, biomanufacturing, diagnostics, and advanced materials. Most recently, Vince led strategy and corporate development at Advancion, a private equity-backed company co-owned by Ardian and Golden Gate Capital. He repositioned the platform as a leading life science consumables brand focused on biomanufacturing and bioindustrials, while co-leading efforts in innovation, sustainability, and DE&I.;

 

Previously, Vince served as Head of Global Business Development for Merck KGaA’s life sciences business, driving the sector’s inorganic growth strategy across M&A;, open innovation, and investments. Earlier in his career, he spent a decade at Agilent Technologies in M&A; and strategic roles spanning genomics, synthetic biology/CRISPR, oligo synthesis & therapeutics, cell biology, diagnostics, and multi-omics. Leveraging deep industry knowledge in bioprocessing, bioreagents, sustainability, and innovation, Vince has consistently delivered value-enhancing strategies and sustainable growth in collaboration with public market investors, private equity sponsors, and executive leadership teams. Vince earned a Bachelor’s degree in Mathematics and Economics from Colgate University and an MBA in Marketing and Entrepreneurial Management from the Wharton School at the University of Pennsylvania

John Voycik

Vice President / Corporate and Business Development

Mr. Voycik has a combined 23 years in the life science and biotech space having served in a variety of roles from sales, marketing and business development. Prior to joining VION Biosciences, Mr Voycik was the VP of sales at Avantor, a Fortune 500 Company. Prior to the 2017 Avantor acquisition, John held various roles in the Portfolio management team where he was instrumental in driving growth across the VWR distribution business. He was involved in the identification and commercialization of global suppliers as well as key in identifying new technologies in the market space.

 

A biochemist by trade, Mr. Voycik quickly moved from the lab at GlaxoSmithKline into sales roles with large technology providers and finally to VION Biosciences where he is Vice President of Corporate and Business Development.

Brian Korec

Vice President / Operations and Supply Chain

Mr. Korec is a highly diversified leader with 20 years of supply chain experience in the life science, biotechnology, and consumer product goods industries. He has served in various leadership roles, including engineering, continuous improvement, manufacturing, distribution, and sales & operations planning.

 

Before joining VION Biosciences, Mr. Korec spent 10 years with Newell Brands, a Fortune 500 company. He led the Global Productivity and North American Distribution pillars for the Home Fragrance business segment, corporate Operations Integration, and recently, North American Distribution across multiple business segments. Prior to Newell Brands, Mr. Korec spent 10 years at AMRESCO (now part of Avantor) in various roles in Operations, Product Design & Engineering, and Custom Manufacturing deployment. He gained significant experience partnering with leading Diagnostic and Biotech companies, successfully leading technology transfer and operational scale-up for the Custom Manufacturing division. Early in his career, Mr. Korec worked as a Manufacturing Scientist, producing precision reagents and molecular-weight reference standards, and supporting new product development.

 

Mr. Korec holds a B.S. in Microbiology from Indiana University.

Heath Bowers, Phd

Vice President of Biopharma Market Solutions

Dr. Heath Bowers is a dynamic leader with over 15 years of experience at the intersection of science, strategy, and business development. His career is marked by transformative achievements that have propelled innovation and growth in the pharmaceutical and biopharma industries.

 

Dr. Bowers’ extensive background in product development and commercialization has established him as a trusted authority in driving success in competitive markets. As North American Business Director of Pharmaceutical Sciences at ABITEC Corporation, he introduced proprietary products that significantly enhanced the company’s profitability and brand awareness. His efforts not only contributed to securing market presence but also fostered long-term growth by positioning ABITEC as a leader in its sector.

 

At GE Healthcare, Dr. Bowers excelled in sales and innovation, pioneering initiatives that were adopted across the organization. Earlier, at AMRESCO, his leadership roles spanned research and development, team management, and sales strategy, where he revitalized underperforming regions, developed high-margin products, and cultivated distributor relationships that drove consistent revenue growth.

 

Dr. Bowers holds a Ph.D. in Biochemistry from Case Western Reserve University and a B.S. in Biochemistry from Ohio University.